Dr Mike Jones – Managing Director – Impact Minerals (ASX:IPT) is an exploration company listed on the ASX in November 2006. The Company manages extensive tenement holdings (>4,000 km2) within Australia featuring significant potential for high-grade mineral deposits of gold, silver, lead, zinc, copper, nickel and PGM’s.
Copyright 2023 – Finance News Network
Source: Finance News Network
11 Sep 2024 - RocketDNA Limited (ASX:RKT) CEO Christopher Clark discusses how the company's AI-powered drones are revolutionising data services for sectors like mining and public safety.
Read More30 Jul 2024 - Dr Mark Cooksey - CEO & Managing Director - ABx Group (ASX:ABX) is a uniquely positioned, Australian company delivering materials for a cleaner future. The two current areas of focus are the creation of an ionic adsorption clay rare earth project in northern Tasmania and the establishment of a plant to produce hydrogen fluoride and aluminium fluoride from recycled industrial waste, to replace imports (ALCORE).
Read More29 Mar 2021 - XTEK Limited (ASX:XTE) Managing Director Phillipe Odouard talks 1H21 results, discussing the company's expanded operational capacity to meet demand for its high-value proprietary solutions in a favourable market environment for domestic and global defence industries.
Read More30 Jul 2024 - Cristian Moreno - Managing Director - Torque Metals (ASX:TOR) is an exploration company with a proven discovery methodology, combining drilling results with machine learning algorithms and geological interpretation.
Read More19 Jun 2024 - Joe David, Managing Director of Elementos discusses the company's recent exciting discovery of high-grade copper and gold at the Cleveland Tin Project in Tasmania. Joe provides insights into the implications of this find, the project's background, and future exploration plans.
Read More06 Jun 2024 - Hazer Group CEO Glenn Corrie about their low-emission hydrogen and graphite technology and a new partnership with POSCO.
Read More23 Apr 2021 - Capral Limited (ASX:CAA) Managing Director Tony Dragicevich talks about the company's strong FY20 results despite COVID, its product mix, operating environment and outlook.
Read More11 Dec 2020 - Cyclopharm Limited (ASX:CYC) CEO & Managing Director James McBrayer talks about USFDA approval for Technegas, the company's USA commercialisation plan, and opportunities beyond its key diagnostic market for pulmonary embolism.
Read More31 Oct 2022 - Shaw and Partners Chief Investment Officer Martin Crabb discusses the market outlook, giving general advice on investment implications.
Read More01 Jul 2021 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO & Managing Director Dr Michael Baker discusses the company's acquisition of the invariant natural killer T (iNKT) cell therapy platform from Imperial College London.
Read More
